https://interactions.guidetherapeutiquevih.com/en/interaction-details?id=14056

Ledipasvir / Sofosbuvir

Atorvastatin

Dosage adjustment may be necessary.

Available pharmaceutical opinion

Document made available to the pharmacist to communicate a drug interaction to the doctor.

DOWNLOAD
Mechanism

Ledipasvir may inhibit transports P-gp and/or BCRP and increase plasma concentration of Atorvastatin.

Ledipasvir / Sofosbuvir

Pharmacodynamic effects

–

Recommendations

–

Alternative solution(s)

–

Atorvastatin

Pharmacodynamic effects

Possible increase of adverse effects.

Recommendations

Use this combination with caution.

A reduction in dosage may be necessary.

Monitor closely.

Alternative solution(s)

–

Monitor

Symptoms of toxicity associated with hypolipidemic agents : gastrointestinal effects, fatigue and muscular weaknesses, myalgias, muscular cramps, myopathies, rhabdomyolysis and myoglobinuria leading to renal insufficiency.

Tests

Lipidic profile

CK

Pharmacokinetic parameters

–

Comment

–

Reference
  • 3118
    Ledipasvir/sofosbuvir (Harvoni), European public assessment report (EPAR) Product Information, London, United Kingdom, 24 avril 2015.